Compare Conagra Brands Inc (CAG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Recursion Pharmaceuticals Inc — how do they compare? Conagra Brands Inc trades at $14.15 (market cap $6.77B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.78B). The key difference: Conagra Brands Inc is far larger — about 3.8× Recursion Pharmaceuticals Inc's market cap, and Conagra Brands Inc pays a 9.89% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CAG | RXRX | |
|---|---|---|
Market Cap | $6.77B | $1.78B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $6.79 |
52-Week Low | $12.58 | $2.84 |
Enterprise Value | $14.05B | $1.19B |
Dividend Yield | 9.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $14.33, up 3.62% today, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, missing Q2 2025 and Q1 2026 estimates but beating Q3 2025. Valuation ratios appear attractive with P/E of 10.06 and P/B of 0.84, though net income margin is negative at -0.39%. Recent news highlights upcoming Q4 earnings and dividend sustainability concerns under new leadership.
CAG presents a high-yield opportunity with a 10% dividend, but faces risks from potential dividend cuts, high debt, and revenue pressures. Analyst consensus is cautious with a $13.70 price target below current levels. Investors should weigh the defensive staple positioning against fundamental headwinds and earnings volatility for balanced risk-reward assessment.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
